Zerlasiran (sodium)
Zerlasiran sodium is an apolipoprotein A (ApoA) synthesis reducer[1].
Product Specifications
Product Name Alternative
SLN360 (sodium)
UNSPSC
12352208
Target
Apolipoprotein; Small Interfering RNA (siRNA)
Type
Oligonucleotides
Related Pathways
Epigenetics; Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/zerlasiran-sodium.html
Purity
95.52
Solubility
10 mM in H2O
Smiles
[Zerlasiran(sodium)]
Molecular Formula
C443H556F12N144Na38O277P40S10
Molecular Weight
14155.88 (free acid)
References & Citations
[1]Nissen SE, Wolski K, Watts GF, et al. Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein (a) : A Randomized Clinical Trial. JAMA. 2024;331 (18) :1534-1543. |[2]Rider DA, Eisermann M, Löffler K, et al. Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease. Atherosclerosis. 2022;349:240-247.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Oligonucleotides
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400745-100 1x 100 µL
CD45 / LCA (2B11 + PD7/26), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740676-100 1x 100 µL
MUC18 / Mucin 18 / CD146 (OJ79c), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 